Related Experiment Videos
Pre-hospital thrombolysis: current status and future prospects
Insights
Pre-hospital thrombolysis for acute myocardial infarction shows time gains but lacks clear clinical benefit. Coordinated care policies are needed, and widespread use by GPs requires caution due to unproven benefits and risks.
Area of Science:
- Cardiology
- Emergency Medicine
- Pharmacology
Background:
- Thrombolytic therapy is standard for acute myocardial infarction (AMI).
- Pre-hospital thrombolysis aims to reduce ischemic time and improve cardiac function.
- Early trials show time savings but lack definitive clinical benefit evidence.
Purpose of the Study:
- To review the rationale and evidence for very early thrombolysis in AMI.
- To assess the impact of small-scale studies on coronary patency, ventricular function, and infarct size.
- To examine the potential risks and benefits of pre-hospital thrombolysis.
Main Methods:
- Review of existing literature on pre-hospital thrombolysis for AMI.
- Analysis of pathophysiological mechanisms underlying early reperfusion.
- Evaluation of data from small-scale studies and ongoing large-scale trials.
Main Results:
- Pre-hospital thrombolysis can achieve significant time gains (up to 60 minutes).
- Evidence for improved clinical outcomes remains limited despite potential benefits in patency and infarct size.
- Risks associated with early administration require careful consideration.
Conclusions:
- Coordinated management policies involving primary care, EMS, and cardiac units are essential for AMI.
- Widespread use of thrombolytics by general practitioners without ECG confirmation is not supported by current evidence.
- Further evaluation of hospital triage and large-scale pre-hospital thrombolysis trials is warranted.
Abstract:
The impact of thrombolytic therapy in acute myocardial infarction has been such that it now constitutes standard therapy for patients who present to hospital with acute myocardial infarction. In an attempt to minimise the duration of ischaemia, and subsequent impairment of contractile function, trials of pre-hospital thrombolysis have been initiated. These reveal time gains of up to 60 minutes but convincing evidence of clinical benefit has not yet been forthcoming. This review examines the rationale for very early thrombolysis, in the context of the underlying pathophysiological mechanisms. It examines the impact of recent small scale studies on coronary patency, left ventricular function and infarct size and examines the potential risks. Large scale studies of pre-hospital thrombolysis are in progress and their findings will need to be interpreted in comparison with optimal 'fast-track' in-hospital treatment. The review highlights the need for co-ordinated policies for acute management of myocardial infarction involving primary care, the emergency medical systems and cardiac units. Enthusiasm for wide scale administration of thrombolytics by general practitioners, without electrocardiographic confirmation of the diagnosis, must be tempered by a clear analysis of the potential risks and benefits. Current evidence does not support such widespread clinical application, outwith the current evaluation studies. An urgent re-evaluation of hospital triage of patients with acute myocardial infarction is merited.